Why the $200,000 journey to motherhood has no insurance calculator, no savings vehicle, and no plan — and what it costs the next generation of women every day it stays that way.
She knows her eggs are best right now. She knows waiting until 38 means worse odds. She's been shown ads that say "freeze your eggs for free — just donate half." But what she doesn't have is a single tool that tells her what this actually costs, what her insurance actually covers, how to pay for it, or what happens if she changes her mind.
Fertility treatment in the United States is effectively a cash market masquerading as healthcare. The decision to freeze eggs is time-sensitive, biologically — and financially catastrophic for the average 27-year-old carrying student loans, rent, and a starting salary. The system offers elite employer benefits to a small minority, state mandates that exempt most employers via ERISA loopholes, and a financing landscape cobbled together from medical credit cards and personal loans.
"What average 27-year-old has $200,000 to invest in fertility when student loans, housing, and living expenses consume more than 90% of income? The answer is: almost none. And the industry has built nothing for her."
The core investment thesisWhat exists today is a patchwork. Carrot Fertility manages employer benefits. Maven Clinic provides virtual care. Evvy maps vaginal microbiome health. Cofertility offers egg donation as a path to free freezing. None of them answer the most fundamental question a woman has when she walks into a fertility clinic: What will this cost me, given my exact insurance, my state, my employer, and my age? And how do I pay for it?
The $10,000–$15,000 number most women hear is the starting point, not the total. By the time the journey is complete — if she uses those eggs — the real number approaches $60,000–$200,000. Here is the full stack that no fertility clinic puts on its homepage.
| Line Item | Low End | High End | Notes |
|---|---|---|---|
| Consultation & diagnostics | $300 | $800 | AMH, FSH, antral follicle count; usually covered if infertility is diagnosed |
| Egg retrieval cycle (1x) | $6,000 | $15,000 | Procedure, monitoring, anesthesia, lab fees. NYC clinics at the top of range |
| Medications (per cycle) | $3,000 | $6,000 | Injectable hormones. Rarely included in bundled pricing |
| Annual egg storage | $500 | $1,000 | Per year; 10-year hold = $5,000–$10,000 before using the eggs |
| Second cycle | $9,000 | $21,000 | Over 50% of patients return for a second cycle; 20%+ do a third |
| IVF / egg thaw & transfer | $13,000 | $25,000 | Fertilization, blastocyst development, embryo transfer |
| ICSI | $1,000 | $2,500 | Required if male factor infertility is present |
| Preimplantation genetic testing | $3,000 | $8,000 | $380/embryo for PGT; strongly recommended to reduce miscarriage |
| Male fertility workup & treatment | $500 | $10,000 | Sperm analysis, IUI, surgical retrieval if needed — largely ignored in budgets |
| Mental health & support | $1,200 | $5,000 | Often required; almost never covered |
| REALISTIC TOTAL | $37,500 | $94,300 | Without insurance. Multiple failed transfers push well past $100k |
The average successful IVF patient using her own eggs undergoes three rounds of treatment before succeeding. Add the freezing cost incurred years earlier, storage fees, and male factor workups, and the $200,000 figure becomes a ceiling, not an outlier.
Typically 1 cycle. High egg count, best viability. Biologically optimal, financially timed worst.
→ Best biology, worst bank account1–2 cycles, higher earning potential but also higher housing and childcare pressure.
→ Most common profile, most underserved3+ cycles to hit 20 eggs. Lower live birth rates. Higher likelihood of donor egg use.
→ When waiting becomes compounding cost67% of Americans with employer-sponsored insurance are enrolled in self-insured plans. Under ERISA, these employers are exempt from state fertility mandates.
As of 2025, 21 states have fertility coverage mandates on the books. Most women assume those mandates protect them. They don't — not for most of them.
The question that matters most, and that no tool currently helps a woman answer automatically: Is my employer's health plan fully insured or self-insured? That single variable determines whether years of state advocacy apply to her at all.
Of employers with 500+ staff covering IVF.
Of large employers covering proactive egg freezing.
Less than one full cycle.
Exempt from state mandates via ERISA.
The top 1% of employers — Google, Microsoft, Intel — have built their own fertility benefit universes. The other 95% of the workforce navigates a system that was not designed for them.
The donation-as-discount model: The “freeze free, donate half” option asks women at peak biological utility to make an irrevocable reproductive decision under financial pressure. This is not a solution. It is a market inefficiency dressed as generosity.
The opportunity is not another clinic network or employer benefits platform. It is financial literacy and financial infrastructure upstream of every fertility decision.
Ingests insurance card, employer, state, age, and diagnosis status and outputs coverage, ERISA status, state mandate applicability, out-of-pocket cost, and ranked financing options.
A dedicated financial product structured like an HSA but purpose-built for fertility preservation and treatment. If unused, funds roll to health savings, childcare, or adoption costs.
A bank-agnostic lending marketplace with underwriting models that account for expected future income trajectory, not current income alone.
Male factor infertility contributes to 40–50% of cases globally, yet financial planning treats fertility as exclusively a women’s problem. The couple is the actual customer.
"The fertility market has built excellent clinical tools and employer benefit wrappers. It has not built the personal finance layer that sits beneath every woman who doesn't work at Google."
Here is what a 27-year-old with no employer benefit, no infertility diagnosis, and $1,200/month in discretionary income actually needs.
A dedicated tax-advantaged savings account restricted to fertility preservation and treatment. Contributions up to $5,000/year pre-tax. Unused funds roll over indefinitely.
The HSA market is $123B+. Fertility is a predictable, time-bounded health event.
The Fertility Preservation Act proposed tax deductions for fertility expenses. Bipartisan support exists.
Requires legislative action for full tax advantage, but can be built after-tax immediately.
A publicly investable basket of companies benefiting from the fertility economy.
An emotionally resonant, demographically concentrated investor base: women 25–40 actively thinking about this.
FemTech market growing at 13–18% CAGR to $97B+ by 2030.
ETF expense ratio plus distribution through the fertility savings account product.
A fertility credit facility underwritten on income trajectory, not current income alone.
PatientFi, Future Family, and Sunfish exist but remain clinic-distribution dependent.
Fertility borrowers are disproportionately educated, employed, and highly motivated to repay.
A loan product that builds in exit counseling at years 5 and 10 creates a differentiated full-cycle product.
Only 10–20% of women who freeze eggs ever return to use them. The financial product white space here includes egg donation brokerage, planned giving vehicles, and defined exit paths at each stage.
Framing egg freezing not as a $200K commitment but as a $15K option that can be exercised, held, or allowed to lapse changes the consumer psychology and expands the addressable market.
The fertility finance gap is not a social problem in search of a business model. It is a multi-billion-dollar financial services opportunity created by a healthcare system that has treated reproductive planning as a luxury rather than a predictable life event requiring infrastructure.
Fertility is the largest single segment.
Demand is structural, not cyclical.
Progyny alone reported $298M in Q4 2024 revenue.
Shows institutional conviction in fertility lending.
The structural tailwinds are clear: women are delaying childbearing, infertility rates are rising, and employer benefits are expanding but remain inadequate for the median worker. The next wave will be built direct-to-consumer by owning the consumer's financial decision before she walks into a clinic.
"The company that builds the fertility equivalent of TurboTax — a tool that demystifies insurance, quantifies cost, and connects to financing — will own the top of the funnel for an industry processing tens of billions of dollars annually."
The legal environment surrounding fertility in the United States is volatile — and it is driving demand for financial planning tools, not suppressing it. Women who cannot predict what their state will permit in three years are making preservation decisions today.
Frozen embryos ruled “children” under state law.
A financial tool that maps legal risk is a product.
Proof that coverage expansion is moving state-by-state.
Regulatory fear is a purchase trigger.
The insurance calculator proposed here is not static. It is a real-time regulatory intelligence layer that updates as state law shifts.
"In states where IVF access is legally uncertain, egg freezing is not a lifestyle choice. It is a hedge against legislative risk."
| Company | Model | Funding | Insurance Calc? | Savings Vehicle? | D2C? |
|---|---|---|---|---|---|
| Progyny | Employer benefits platform | Public | Partial | No | No |
| Carrot Fertility | Employer benefit program | $110M+ | Employer-only | No | No |
| Maven Clinic | Virtual fertility + maternity | $300M+ | No | No | Partial |
| Cofertility | Egg donation / free freeze | $16M | No | No | Yes |
| Future Family | Fertility financing | $400M initiative | No | No | Clinic-gated |
| Sunfish | IVF bundles + loan marketplace | Undisclosed | No | No | Partial |
| Evvy | Vaginal microbiome testing | $14M+ | No | No | Yes |
| The Opportunity | Insurance calculator + savings + loans, D2C | — | Core product | Core product | Yes |
Every company in this space owns one sliver of the fertility journey and has deliberately not touched the financial planning layer. The woman who needs this most — undiagnosed, uninsured for it, 27 years old and Googling — has no product built for her decision moment.
| Company | Category | Funding / Status | Insurance Nav | Savings Vehicle | Couples Planning | D2C Pre-Clinic |
|---|---|---|---|---|---|---|
| Progyny | Employer benefits | Public | Employer-only | None | None | None |
| Carrot Fertility | Employer benefit program | $110M raised | Employer-only | None | None | None |
| Maven Clinic | Virtual fertility + maternity | $300M+ raised | None | None | Partial | Partial |
| Cofertility | Egg donation / free freeze | $16M | None | None | None | Yes |
| Future Family | Fertility financing | $400M initiative | None | None | None | Clinic-gated |
| Evvy | Vaginal microbiome Dx | $14M raised | None | None | None | Yes |
| The Open Lane | Insurance navigator + savings + couples planning, D2C | — Unfunded — | Core product | Core product | Core product | Core model |
"Every player in this space distributes through employers or clinics. The woman who needs this most — undiagnosed, uninsured for it, 27 years old and Googling — has no product built for her decision moment. That moment is worth billions."
Built on insurance + financial product navigation.
Student loan refinancing for young professionals.
Savings account infrastructure analogue.
Male infertility is structural, not niche.